Altern Ther Health Med. 2024 Nov;30(11):390-398.
To observe the clinical effect of mometasone furoate cream sodium Alginate Skin Repair Mask in the treatment of atopic dermatitis (AD). By assessing the combined use of these two treatments, the study aims to address a gap in knowledge regarding the effectiveness and safety of adjuvant therapies for AD, particularly in the context of Alginate Skin Repair Mask.
Eighty patients were enrolled, including 42 males and 38 females aged 20-47 years, with an average age of (32.52±5.57) years, from July 2021 to July 2022, and the patients were divided into a single group (n=40) and a combined group (n=40) by random number table method. The patients in the single group were treated with mometasone furoate cream alone, and the patients in the combination group were treated with Alginate Skin Repair Mask on the basis of the treatment of the patients in the single group. The outcome measurements included clinical treatment effect, condition change (SCORAD score), quality of life (DLQI score), adverse reactions and disease recurrence were compared between the two groups. Both groups received treatment for 1 month. After the treatment of the patients, they were followed up for a period of 3 months.
The total effective rate of the single group was 80.0% (32/40), and that of the combined group was 97.5% (39/40) (P < .05). After treatment, the skin lesion area score, skin lesion degree score, pruritus insomnia score, and SCORAD total score in the combined group were significantly lower than those in the single group (35.03±9.41 vs 44.03±12.04) (all P < .05). The DLQI score of the combined group after treatment was significantly lower than that of the single group (3.72±1.53 vs 6.98±2.16) (P < .05). The incidence of adverse reactions in the single group was 22.5% (9/40), and the disease recurrence rate was 32.5% (13/40), while the incidence of adverse reactions in the combination group was 2.5% (1/40). The disease recurrence rate was 7.5% (3/40), and the incidence of adverse reactions and disease recurrence rate in the combination group were significantly lower than those in the single group (7.314, 7.812).
Mometasone furoate cream sodium Alginate Skin Repair Mask has an ideal clinical effect in the treatment of atopic dermatitis. Compared with single mometasone furoate cream, the combination of sodium Alginate Skin Repair Mask can further improve the patient's condition, improve the quality of life of the patient, and reduce the risk of adverse reactions and disease recurrence. The higher total effective rate in the combined group indicates that the addition of Alginate Skin Repair Mask to the treatment regimen resulted in improved outcomes for patients with atopic dermatitis (AD). This translates to better control of the disease, reduction in symptoms, and overall improvement in the patient's condition. However, it is important for clinicians to be aware that the use of topical glucocorticoids like mometasone furoate cream can potentially lead to adverse reactions. Some documented adverse reactions associated with long-term use of topical glucocorticoids include acne-like eruption, telangiectasia (dilation of small blood vessels), and local skin atrophy. By addressing multiple aspects of AD management, including skin barrier repair, moisturization, and inflammation control, the combination of mometasone furoate cream and Alginate Skin Repair Mask provides a more comprehensive treatment approach. This comprehensive approach may contribute to the observed reduction in recurrence rate in the combination group compared to the single group, where only mometasone furoate cream was used.
观察糠酸莫米松乳膏联合海藻酸钠医用皮肤修复膜治疗特应性皮炎（AD）的临床疗效。通过评估这两种治疗方法的联合使用，旨在解决 AD 辅助治疗有效性和安全性方面的知识空白，特别是在海藻酸钠医用皮肤修复膜方面。
选取 2021 年 7 月至 2022 年 7 月收治的 80 例患者，随机分为单一组（n=40）和联合组（n=40）。单一组患者给予糠酸莫米松乳膏治疗，联合组患者在单一组患者治疗的基础上给予海藻酸钠医用皮肤修复膜治疗。观察两组患者的临床治疗效果、病情变化（SCORAD 评分）、生活质量（DLQI 评分）、不良反应及疾病复发情况。两组患者均治疗 1 个月，治疗结束后随访 3 个月。
单一组总有效率为 80.0%（32/40），联合组为 97.5%（39/40）（P＜0.05）。治疗后，联合组皮损面积评分、皮损程度评分、瘙痒失眠评分及 SCORAD 总分均明显低于单一组[（35.03±9.41）分比（44.03±12.04）分]（均 P＜0.05）。治疗后联合组 DLQI 评分明显低于单一组[（3.72±1.53）分比（6.98±2.16）分]（P＜0.05）。单一组不良反应发生率为 22.5%（9/40），疾病复发率为 32.5%（13/40）；联合组不良反应发生率为 2.5%（1/40），疾病复发率为 7.5%（3/40）。联合组不良反应发生率及疾病复发率均明显低于单一组（7.314，7.812）。
糠酸莫米松乳膏联合海藻酸钠医用皮肤修复膜治疗特应性皮炎具有理想的临床效果，与单一糠酸莫米松乳膏相比，联合海藻酸钠医用皮肤修复膜能进一步改善患者病情，提高患者生活质量，降低不良反应及疾病复发风险。联合组总有效率更高，提示联合治疗方案在特应性皮炎患者中的治疗效果更好，可更好地控制疾病，减轻症状，改善患者整体病情。然而，临床医生应注意，外用糖皮质激素（如糠酸莫米松乳膏）的使用可能会导致不良反应。一些与长期使用外用糖皮质激素相关的不良反应包括痤疮样疹、血管扩张（小血管扩张）和局部皮肤萎缩等。糠酸莫米松乳膏联合海藻酸钠医用皮肤修复膜的联合治疗方法从多个方面治疗 AD，包括皮肤屏障修复、保湿和炎症控制，提供了更全面的治疗方法。与仅使用糠酸莫米松乳膏的单一组相比，联合组观察到复发率降低，这可能与这种更全面的治疗方法有关。
